Sugi Predict

Sugi Predict / Compounds / SCHEMBL23536211

SCHEMBL23536211

SCHEMBL23536211

COC(=O)c1cc(N)c(I)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 1/20 0.49
▸ CFTR P13569 3/20 0.49
▸ KDM4E B2RXH2 6/20 0.46
▸ ALDH1A1 P00352 5/20 0.45
▸ GAA P10253 5/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ GLA P06280 2/20 0.45
▸ CASP1 P29466 1/20 0.45
▸ CASP7 P55210 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ ABL1 P00519 1/20 0.44
▸ SOS1 Q07889 1/20 0.43
▸ TSHR P16473 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 3/20 0.38
▸ CYP1A2 P05177 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30064505 1.00 NQO2 (0.49) NQO2CFTRKDM4EALDH1A1GAA
SCHEMBL31431696 0.93 CFTR (0.53) NQO2CFTRKDM4EALDH1A1GAA
SCHEMBL7896855 0.85 KDM4E (0.52) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL24413993 0.85 CFTR (0.58) NQO2CFTRKDM4EALDH1A1GAA
SCHEMBL1567667 0.84 KDM4E (0.59) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL23874532 0.83 GAA (0.61) NQO2CFTRKDM4EALDH1A1GAA
SCHEMBL1770853 0.82 KDM4E (0.49) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL3974563 0.81 GAA (0.54) NQO2CFTRKDM4EALDH1A1GAA
SCHEMBL29906742 0.81 GAA (0.50) CFTRKDM4EALDH1A1GAAHSD17B10
SCHEMBL2690892 0.81 KDM4E (0.50) NQO2CFTRKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12539295-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-03 — — US disclosed
US-20250333417-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-30 — — US disclosed
EP-4638420-A1 COMPOUNDS THAT INHIBIT PKMYT1 Exelixis, Inc. (US) 2025-10-29 — — EP disclosed
EP-4620470-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-24 — — EP disclosed
EP-4615455-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-17 — — EP disclosed
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-20250059164-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-20 — — US disclosed
WO-2024264017-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-12-26 — — WO disclosed
US-12150995-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-11-26 — — US disclosed
US-20240383887-A1 DEUTERATED IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-11-21 — — US disclosed
WO-2022087216-A1 DOUBLE DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-04-28 — — WO disclosed
WO-2022087216-A1 DOUBLE DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-04-28 — — WO disclosed
US-20220054453-A1 METHODS OF TREATING MUTANT LYMPHOMAS KYMERA THERAPEUTICS, INC. 2022-02-24 — — US disclosed
WO-2022027058-A1 METHODS OF TREATING MUTANT LYMPHOMAS KYMERA THERAPEUTICS, INC. (US) 2022-02-03 — — WO disclosed
WO-2022027058-A1 METHODS OF TREATING MUTANT LYMPHOMAS KYMERA THERAPEUTICS, INC. (US) 2022-02-03 — — WO disclosed
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-07-29 — — US disclosed
WO-2021127283-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 — — WO disclosed
WO-2021127190-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 — — WO disclosed
WO-2021127190-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 — — WO disclosed
WO-2021127283-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NQO2 3258/4885CFTR 3537/4885KDM4E 190/4885
US-12539295-B2 IRAK degraders and uses thereof IRAK2, IRAK4, IRAK3 NQO2 2515/4885CFTR 772/4885KDM4E 810/4885
US-20220054453-A1 METHODS OF TREATING MUTANT LYMPHOMAS IRAK4, IRAK2, IRAK3 NQO2 3575/4885CFTR 3967/4885KDM4E 58/4885
US-20240383887-A1 DEUTERATED IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK1, IRAK3 NQO2 2970/4885CFTR 4424/4885KDM4E 375/4885
US-12150995-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 NQO2 3258/4885CFTR 3537/4885KDM4E 190/4885
US-20250059164-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NQO2 3258/4885CFTR 3537/4885KDM4E 190/4885
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NQO2 3258/4885CFTR 3537/4885KDM4E 190/4885
US-20250333417-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NQO2 3258/4885CFTR 3537/4885KDM4E 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.